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LEAP – Learning Early About Peanuts 
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Key Messages 
• " Allergy testing and/or supervised first introduction of the specific allergenic 
food is advisable for infants with eczema and/or pre-existing food allergy prior to oral 
tolerance induction  
• " A weekly dose of 2g of peanut or egg protein appears to be protective against 
peanut or egg allergy 
• " Oral tolerance induction is allergen specific and has only been proven to be 
successful in single introduction trials of peanut and egg; multiple allergen oral 
tolerance induction is a significant unmet need which requires investigation using 
novel approaches.  
• " The addition of peanut, and other common food allergens (egg, fish, sesame, 
milk) to the infant diet has no adverse nutritional or growth effects and does not 
increase rates of food allergy. Breastfeeding rates are not adversely affected by these 
interventions in a clinical trial setting.  
• " In the Western world, non-white children have the highest risk of food allergy 
but their families are the least likely to take up oral tolerance induction programmes; 
strategies to promote oral tolerance induction in non-white families are required 
 
 
 
Introduction 
Driven by both the continuing rise in food allergy prevalence
1, 2
 and the lack of an effective 
cure, the last decade has seen an increase in clinical trials investigating the prevention of food 
allergy. Earlier wisdom, predominantly derived from the findings of observational studies, 
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considered that allergy prevention was best achieved through allergen avoidance.
3, 4
 After 
testing under randomised controlled trial (RCT) conditions, allergen avoidance has not been 
deemed a suitable means of preventing food allergy.
5, 6
   
As the allergy field has evolved, a view which opposes the allergen avoidance hypothesis has 
gained momentum: the dual allergen exposure hypothesis proposes that allergic sensitisation 
may occur through the skin unless oral tolerance is first induced via the GI tract.
7
 The first 
aspect of this hypothesis, that allergic sensitisation occurs through the skin, has been explored 
in epidemiological studies. These studies found that atopic dermatitis precedes the 
development of food allergic sensitisation (FS). There is also a strong association between 
atopic dermatitis severity and the risk of FS and food allergy.
8, 9
 RCTs examining the effect 
of optimal management of atopic dermatitis on FS are underway. The second aspect of the 
dual allergen hypothesis, whether oral tolerance may be induced via the GI tract, has been 
explored in recent RCTs. The majority of trials have focused on the introduction of one food 
only, with egg and peanut being the most commonly investigated.
2, 10-14
 Only one trial, the 
Enquiring about Tolerance (EAT) study, has investigated oral tolerance induction to multiple 
foods. This trial compared the effect of early introduction (from 3 months of age) of the six 
most common childhood food allergens (cow's milk, hen’s egg, peanut, sesame, cod fish and 
wheat) with exclusive breastfeeding until about 6 months of age for the prevention of 
childhood food allergy. 
15
  
The results of these early introduction trials are variable. 
1, 5
 The most notable results are 
those from the Learning Early About Peanuts (LEAP) study.   This RCT randomized the 
introduction or avoidance of peanut in infants aged between 4-<11 months, who were at high 
risk of developing peanut allergy (with moderate-severe eczema and/or egg allergy), and 
demonstrated an 81% relative reduction in peanut allergy at 5 years of age compared with 
children who avoided peanut containing products for the same time period.
2
 Other studies 
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have either failed to meet their primary outcomes or not shown such a strong effect and a 
meta-analysis investigating the timing of allergenic food introduction to the infant diet found 
moderate evidence that egg introduction at 4-6 months was associated with reduced egg 
allergy and that peanut introduction at 4-11 months was associated with reduced peanut 
allergy.
5
 There is currently no evidence that early introduction of cow's milk, fish, sesame 
and wheat protects against the development of food allergy but, to date, few studies have 
investigated oral tolerance induction to these foods.
5
 The dearth of clinical trials exploring 
multiple oral tolerance induction and the limited number of foods that have been explored in 
single allergen oral tolerance induction, means that the scope of oral tolerance induction in 
preventing food allergy is unclear. Yet in the absence of further data, introducing allergenic 
foods into an infants' diet appears to be the most effective means of preventing food allergy at 
the current disposal of the allergist. Drawing predominantly on the lessons learned from 
LEAP and EAT but with reference to other oral tolerance induction studies (summarised in 
Table 1) we now discuss some of these challenges associated with oral tolerance induction.  
The window of opportunity  
Choosing when to introduce a food to the infant diet presents a significant challenge:  Oral 
tolerance induction must begin when the child is developmentally able to consume foods 
other than breast or formula milk but before a child has become allergic.  For some infants, 
this window of opportunity can be narrow.  
When does allergic sensitisation/allergy occur? 
Allergic sensitisation and, in some cases food allergy, begins early. Data from older infants in 
the HealthNuts study reveal high rates of food allergy at 12 months of age with 3.1% (95% 
CI, 2.6% to 3.6%) of infants demonstrating oral food challenge (OFC) proven allergy to 
peanut, 10.1% to egg (95% CI, 9.2% to 11.0%), and 0.7% to sesame (95% CI, 0.5% to 
0.9%).
16
 As the prevalence of food allergy at 10-14 years of age may be as high as 4.5%
17
 it 
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is evident that, for many children, early allergy is not transient and thus effective allergy 
prevention is essential.  
Whilst it is clear that FS begins in infancy, to date no studies have utilised sequential testing 
to discover the natural history of the onset of FS in very early childhood. Oral tolerance 
induction studies, including LEAP and EAT, shed some light on this biological process. 
Children were enrolled into the LEAP study between the ages of 4 and <11 months with a 
mean age of 7.8 months. All children underwent skin prick testing (SPT) to peanut at their 
screening visit and 9.1% (76/834) were excluded from LEAP as they were assumed to 
already be allergic with a SPT >4mm. 
18
 Of those who were eligible for LEAP participation 15.3% (98/640) were sensitised (1-
4mm) to peanut and 12.8% (6/47) of the sensitised group who were randomised to the 
intervention were found to be allergic during their baseline OFC.
2
  Similar findings were 
evident in the Beating Egg Allergy Trial (BEAT) of egg oral tolerance induction in infants at 
high risk of allergic disease
11
; 3.9% of infants had an SPT of >2mm by 4 months of age and 
10% (14/165) of infants were deemed to be egg allergic during the study entry OFC despite 
having SPT<2mm.   
LEAP and BEAT both enrolled infants who already had, or were at risk of, atopic disease and 
were thus at high risk of demonstrating FS or allergy; however the EAT Study enrolled 
infants from the general population. Despite being a ‘lower risk’ population, infants who took 
part in EAT also demonstrated FS or allergy from an early age;
15
 5.1% (33/652) of 3 month 
old infants had a positive SPT to at least one of the study foods (SPT range 1mm-16mm). Of 
these, 2.9% (19/652) had an SPT of ≥ 5mm. Any infant with a positive SPT underwent an 
OFC and 1% (7/652) were deemed allergic to at least one of the six study foods at 3 months 
of age.   
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These data highlight that the window of opportunity to prevent allergy may be narrow and, 
unless oral tolerance induction begins in infancy, the window may be closed for those infants 
at most risk of food allergy. As we now discuss, the practicalities of intervening in early 
infancy also presents challenges.  
Access to services 
Recent updates to the allergy prevention guidance issued by the US (NIAID) and Australia 
(ASCIA) encourage the early introduction of peanut protein into infant diets. The specifics of 
this guidance varies, with ASCIA recommending this approach for all infants, regardless of 
atopic risk
19
, whilst NIAID emphasizes this approach for high risk children who have eczema 
or egg allergy.
20
  
Which infants should undergo allergy testing prior to commencing oral tolerance induction is 
still under debate.  Infants who took part in LEAP underwent SPT, spIgE and OFC prior to 
the introduction of the study foods. Unexpectedly, in LEAP, 17% children who showed no 
SPT sensitisation at enrolment had peanut-specific IgE sensitization ≥0.35 kU/L.  Moreover, 
56% of children with SPT sensitisation of 1-4mm and 91% with SPT ≥5mm (not eligible for 
LEAP participation) had peanut-specific IgE sensitization ≥0.35 kU/L.18 Of children who 
already demonstrated SPT sensitivity (1-4mm) at LEAP enrolment, 12.8% (6/47) of those 
randomised to the intervention were found to be allergic during their baseline OFC.
2
   
In the Healthnuts study, SPT of eczematous infants (16% of the population) was able to 
identify 77% of all children who subsequently developed peanut allergy.
21
 This highlights the 
potential effectiveness of screening prior to commencing oral tolerance induction. While the 
issues of National Screening Programmes to prevent food allergy are controversial,
21-23
  
testing is likely to be beneficial in high risk groups, namely children with severe eczema or 
egg allergy in the first 11 months of life, as in the LEAP study. The approach proposed by 
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NIAID seems to balance logistical and safety concerns by adopting a three tiered approach: i) 
children with severe eczema, egg allergy or both should aim to introduce peanut at about 4-6 
months after undergoing SPT and/or IgE testing and, depending on the results, an OFC; ii) 
children with mild to moderate eczema should introduce peanut at around 4-6 months; iii) 
children with no eczema should introduce peanut containing foods according to family 
preferences.
20
  
If testing and/or OFC are to be utilised prior to commencing oral tolerance induction then, to 
maximise effectiveness , high risk infants should attend specialist allergy services in early 
infancy or when risk factors for food allergy are first demonstrated. However, in many 
countries, where access to specialist services are limited, this will be difficult to achieve. 
Improving access to specialist services by increasing the number of training places for 
physicians, specialist nurses and dietitians is essential in order to facilitate early intervention. 
Developing rapid access oral tolerance induction clinics would also ensure the infants who 
are at the highest risk of developing allergy are able to safely introduce allergenic foods into 
their diets. Such clinics will allow identification and introduction of the highest priority 
allergens both with respect to allergens which are most likely to persist in later childhood, 
allergens to which the child is already sensitised and allergens which form a regular part of 
the familial diet. 
WHO advice regarding exclusive breastfeeding versus oral tolerance induction 
The World Health Organisation (WHO) advocates exclusive breastfeeding for the first six 
months of life;
24
 this advice is also promoted by the health departments of many countries, 
including the United Kingdom’s Department of Health. At least in developed countries, few 
mothers adhere to this advice with 44.3% of UK mothers breastfeeding when their infant is 6-
8 weeks old,
25
 and only 3.6% of mothers exclusively breastfeeding until 6 months of age.
26
 
Rates of exclusive breastfeeding to 6 months are higher in the USA, approximating 25%,
27
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but still fall short of the expectations of the WHO. Introduction of solid food before 6 months 
of age is also common, with 30% of UK infants having solid foods introduced by 4 months of 
age and 75% by 5 months of age.
26
  
The WHO guidelines for infant feeding are appropriate for many children but do not appear 
to be suitable for infants with risk factors for the development of food allergy. Such infants 
may benefit from introduction of specific allergenic foods, alongside breastfeeding, before 
this time.
28
 International guidelines for allergy prevention now encourage active introduction 
of peanut protein into the diet of high risk infants at 4-6 months of age (US NIAID
20
) and all 
allergenic foods to all infants from 4 months of age (Australia ASCIA
19
).  
Further studies which consider the effect of early introduction of allergenic foods on 
breastfeeding rates, and which explore the long term effects of both on child health are 
required. Until such data are published, reassurance is provided from the EAT findings in 
which introduction of solid food from 3 months of age had no effect on (already established) 
breastfeeding rates--over 97% of infants were still being breastfed at 6 months of age.
15
 
Furthermore, between group comparisons in LEAP and EAT show early introduction of one 
or more allergenic (and thus energy dense) food had no deleterious nutritional or growth 
outcomes at 72 and 36 months (respectively).
15, 29
  
Developmental ability of the child 
Beginning to wean an infant to food substances alongside breast or formula milk feeding, 
requires that an infant expresses interest, can hold their head up, can sit with support and has 
lost the tongue thrust reflex which prevents food from passing to the back of the mouth. 
These developmental milestones tend to occur between 4 and 6 months but atopic children 
may already be sensitised or allergic by this age.  
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Additionally, introduction of allergenic foods before 6 months of age in specific quantities is 
discordant with baby led weaning (BLW) and responsive feeding; weaning principles which 
are gaining in popularity. Studies exploring how to apply oral tolerance induction to very 
young infants and alongside responsive weaning methods are required.  
The challenges of intervening to prevent allergy during the window of opportunity are 
compounded by a lack of evidence regarding the most appropriate oral tolerance induction 
regime. In the following section we discuss some of these challenges.  
Dose and adherence in early introduction regimes 
Choosing the quantity, frequency and type of the early introduction regime poses additional 
challenges, not only in ensuring the regime is effective but also in balancing an effective 
regime with one that is not so onerous as to be unachievable.  
Varying types of allergenic food introduction 
Studies examining oral tolerance induction to egg have differed in the type of egg protein 
used. Three studies (HEAP
12
, STEP
14
 and STAR
13
) used raw egg protein whilst two (EAT,
15
 
PETIT
10
) used cooked egg. None of the studies using raw egg protein showed a difference in 
effect (see Table 1).   In all three of the studies using raw egg protein, a high proportion of 
infants experienced allergic reactions either during the entry OFC or during home 
consumption. Two studies were discontinued early: in the HEAP study 10/16 (62.5%) of 
children with egg allergy experienced anaphylaxis during OFC
12
, whilst in the STAR study 
recruitment was paused to allow the independent data safety monitoring committee to 
examine the rates of allergic reaction and anaphylaxis to study powder.  The committee found 
that the study could continue but was subsequently discontinued for logistical reasons
13
.  
The safety profile of oral tolerance induction using raw egg powder contrasts with the EAT 
and PETIT studies, which utilised cooked egg protein. PETIT found oral tolerance induction 
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to be effective, and EAT also found an effect to egg in the PP group. Both studies 
demonstrated the safety of cooked egg oral tolerance induction with no cases of anaphylaxis 
either at home or during OFC.   
Dose 
The dose of protein consumed by children in the oral tolerance induction studies published to 
date has been somewhat varied. In one study, PETIT, substantially smaller doses of protein 
were found to be effective in preventing hen’s egg allergy; however, there are several 
differences between PETIT and LEAP, EAT and BEAT (see Table 1). Children in PETIT 
were already sensitised to egg white at enrolment with a mean sIgE of 0.73kUA/l (range 
0.17-5.55kUA/l). Subgroup analysis of the 36 children with an egg sIgE of <0.35kUA/l found 
no risk difference between the groups (2/24 active versus 3/12 placebo; risk difference 16.7% 
[95% CI –10.2 to 43.5] p=0.31).10 This finding suggests that PETIT is predominantly a 
secondary prevention, rather than a primary prevention study. Similarly, for a subgroup of 
participants, the LEAP intervention acted as a secondary prevention strategy. Whilst the 
majority (542) of infants in the LEAP study had a negative peanut SPT at enrolment - and 
thus for them the intervention was preventative - 98 children were sensitised (SPT 1-4mm) at 
enrolment
2
. However, unlike PETIT, the LEAP the intervention was effective in both groups. 
The difference in findings between the non-sensitised infants who were enrolled in LEAP and 
PETIT suggest that very small quantities of protein may not be sufficient for primary oral 
tolerance induction.  
LEAP, EAT and BEAT all utilised larger quantities of protein than PETIT. LEAP study 
children consumed 6g of peanut protein per week, divided into 3 doses of 2 g and EAT study 
children consumed 4g of each of the six study foods per week divided into 2 doses of 2g. The 
LEAP regime was successful, achieving an 86.1% reduction in peanut allergy in the SPT-
Negative Stratum.
2
 The EAT ITT analyses showed no effect but, although the absolute 
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numbers were small, PP analyses reveal a 75% reduction in egg allergy and a 100% reduction 
in peanut allergy.
15
  These quantities concur with the upper quartiles of peanut consumption 
in Israeli infants who appeared to be protected against peanut allergy in an ecological study 
exploring prevention of peanut allergy.
30
 
A dose that sits somewhere between the PETIT and LEAP/EAT doses has also been shown to 
be effective. Weekly consumption of 2g of protein promoted oral tolerance induction in the 
BEAT study which achieved a 47.8% relative reduction in the frequency of IgE sensitisation 
to egg white using a weekly quantity of 2.45g protein which was consumed in 0.35g daily 
aliquots, although no effect was noted on rates of clinical allergy to egg.
11
 Dose response 
analyses of EAT study data reveal similar findings to the BEAT study; a mean weekly dose 
of 2g of peanut or egg protein was protective against peanut or egg allergy.
15
 Furthermore, an 
ecological study of Israeli children who consumed peanut in early life found that 
consumption of 1.7g of peanut protein per week was protective against peanut allergy.
30
 It is 
notable that comparable doses of protein were required for prevention of egg and peanut 
allergy, and the evidence therefore suggests that a weekly dose of approximately 2g of egg or 
peanut protein is likely to be sufficient to prevent egg or peanut allergy in the majority of 
children. This dose, which represents 1 teaspoon of peanut butter or 1 hardboiled egg per 
week, is also likely to be achievable for the majority of infants. This is particularly important 
given the challenges associated with adherence to oral tolerance regimes, which we now 
discuss. 
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Adherence 
The EAT study demonstrates that adherence to the treatment regime is necessary for oral 
tolerance to be effective.  Specifically, a per-protocol analysis showed a 67.1% (p=0.01) 
relative reduction in allergy, compared to a 21.1% (p=0.32) relative reduction in the intention 
to treat analysis.
15
 Moreover, it is reassuring that EIG infants who were non-adherent to the 
intervention had similar rates of allergy compared to the control group.  This implies, 
although it does not prove, that the presence of allergy was not responsible for non-adherence 
in the intervention group.
15
 Potential bias in the PP analysis resulting from poor adherence 
was examined in the EAT study using an instrument variable (IV) analysis.  Specifically, the 
complier average causal effect (CACE) method projects the rate of allergy observed in the 
non-adherent intervention group, onto the control arm.  Using the assumption that 
randomization balances all factors, the CACE method estimates the effect of confounding 
potentially caused by non-compliance and removes it from the PP intervention effect.  In the 
EAT study the unbiased CACE estimate was almost identical to that of the PP analysis (risk 
difference 2.47% versus 2.51%). This indicates that non-adherence was likely not due to 
reverse causality (i.e. that children did not adhere because they were allergic and thus unable 
to consume the foods).
31
 
 
Rates of adherence in oral tolerance studies are variable (see Table 1) however consumption 
of 2g of peanut protein three times a week did not pose significant problems in LEAP with 
92% of participating families adhering to the intervention.
2
 In EAT, for which six study foods 
were investigated, adherence (defined as consumption of 2 g or more per week of allergenic 
protein for 4 or more weeks) was much lower at 31.9%. Adherence in BEAT and PETIT, for 
which lower overall quantities of egg protein were consumed, was also good with BEAT 
achieving 85% adherence
11
 and PETIT achieving 79%.
10
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
15 
 
To date, single oral tolerance induction trials have enjoyed high level of adherence whilst the 
EAT Study had low adherence to the intervention (adherence in the control arm was 92.9%
2
). 
It is easy to assume that the clear difference in rates of adherence in the single oral tolerance 
induction studies and (to date) the only published multiple oral tolerance induction study are 
the result of the number of foods being introduced; however other factors are also likely to be 
relevant. For example palatability, texture, overall portion size and ease of preparation by 
parents of young infants, are likely to be relevant to adherence. This is evidenced by data 
from the EAT study showing specific foods were associated with lower adherence. 
Adherence to wheat was low but this was, at least in part, due to the study design; wheat was 
the last of the foods to be introduced making it more difficult to meet the protocol definition 
of adherence.  With respect to the other study foods, those that were easy to prepare and 
palatable to an infant e.g. cow's milk and peanut, achieved the highest levels of adherence; 
those that required more preparation and/or had a taste or texture which was unfamiliar or 
unpleasant to an infant, e.g. egg, sesame, and fish, had the lowest adherence.  
The factors that influenced adherence in LEAP and PETIT could not be investigated as 
adherence was high. However, adherence was lower in the EAT study affording the 
opportunity for investigation. A dominance analysis of non-adherence in the EAT study 
found that 78% of the variance could be accounted for by four main factors: nonwhite race 
(odds ratio, 2.21; 95% CI, 1.18 to 4.14), parent perception that the child experienced 
symptoms to one of the study foods (odds ratio, 1.70; 95% CI, 1.02 to 2.86), reduced 
maternal quality of life (psychological domain) (odds ratio, 0.69; 95% CI, 0.47 to 1.00), and 
the child having eczema at enrolment to EAT (odds ratio, 1.38; 95% CI, 0.87 to 2.19).   
Health inequalities influence access to health services, engagement with health services and 
adherence to treatment.
32-34
 Maternal ethnic group, education and social class are also 
relevant to infant feeding and have been shown to influence breastfeeding
35
 and infant 
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weaning practices.
36
 Non-white race was the strongest predictor of non-adherence in the EAT 
study,  The BEAT study similarly found that children who were lost to follow up, withdrawn 
or had no primary outcome data were more likely to have a parent born outside of Australasia 
(father p < 0.001 and mother p <0.02) than those who had complete data. Non-white children 
had a greater risk of food allergy in both LEAP and EAT. Notably, children with the greatest 
risk of food allergy are most likely to come from families who are least likely to take up the 
intervention. Prevention studies and strategies must focus on such communities; patient and 
public involvement in these studies and strategies will be essential if oral tolerance induction 
is to be effective.  
Allergen specificity 
Single allergen oral tolerance induction studies have shown promising results, however, 
atopy and food allergy are rarely isolated conditions; for example, between a third and half of 
children with peanut allergy are allergic to at least one tree nut.
37, 38
  
Early introduction of peanut did not hasten the resolution of egg or milk allergy or atopic 
dermatitis, nor did it prevent the development of asthma or allergic rhinitis. Despite potential 
cross reactivity to either T cell or B cell epitopes, early introduction of peanut did not protect 
against new onset tree-nut or sesame allergy.
39
 Conversely, long term follow up of the LEAP 
cohort showed a small and inconsistent but statistically significant rise in tree nut 
sensitisation and parent reported allergy in children in the early introduction arm.
39
 This 
finding is being further investigated in the LEAP Ad-lib study.  
Given the specificity of oral tolerance induction, multiple oral tolerance induction strategies 
are necessary to facilitate adherence and successful oral tolerance induction. 
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Conclusion 
Allergy prevention is beset by difficulties. Use of SPT and/or IgE testing in children at high 
risk of allergy (those with moderate/severe eczema and/or egg allergy) prior to commencing 
oral tolerance induction is desirable but may be difficult to implement. Intervening whilst the 
window of opportunity is open (before allergy occurs), using a programme that provides 
protection against multiple allergens, presents significant challenges and may not be easily 
achievable at such a young age. The findings of recent trials provide evidence that allergy 
prevention through oral tolerance induction programmes which employs a regime of protein 
consumption of 2g/week are effective in preventing peanut and egg allergy. However, there is 
currently no evidence with respect to other common food allergens and it is not clear whether 
this lack of evidence is simply the result of a lack of high quality studies, or reflects true 
differences in the underlying mechanisms of allergic sensitisation/tolerance. For example, it 
may be that the dual allergen exposure hypothesis only applies to specific foodsMoreover, 
not all allergy is IgE mediated and there is no evidence that oral tolerance induction is 
appropriate for non-IgE mediated allergy. Further research and consensus with regards to 
food preparations, target populations, dosing regimes and preparations, and clearly defined 
adherence are now required.
 1,40, 41
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Table 1: Summary of Oral Tolerance Induction studies 
 
Name 
of 
Trial 
Typ
e 
and 
N 
Populati
on 
Screen 
failure
s due 
to 
allergy
/likely 
allergy 
Interv
ention 
group 
(protei
n per 
week) 
Contro
l group 
Age 
at 
stud
y 
entr
y 
(age 
in 
mon
ths) 
Outc
ome 
asse
ssed 
(age 
in 
mon
ths) 
Per 
protocol 
Adherence 
rates 
interventio
n/control 
Primar
y 
outco
me 
Outc
ome 
in ITT 
(p 
value
) 
LEAP 
(Learn
ing 
Early 
About 
Peanu
t), UK 
RCT
, 
ope
n 
lab
el 
(64
0) 
High risk 
(infants 
with 
moderat
e/severe 
eczema 
and/or 
egg 
allergy) 
76/834 
SPT 
≥5mm  
Peanu
t snack 
or 
peanu
t 
butter 
(6g) 
PN 
avoida
nce 
until 60 
month
s 
4-11 60 SPT-ve 
group 
I= 96%; 
C=93% 
SPT+ve 
group 
I=95% 
C=98% 
PN 
allergy 
(OFC) 
ARR 
11.8
% 
(95% 
CI 3.4 
to 
20.3; 
P<0.0
01) 
Enquir
ing 
About 
Tolera
nce 
(EAT), 
UK 
RCT
, 
ope
n 
lab
el  
(13
03) 
general 
populati
on 
No 
exclusi
ons 
require
d per 
protoc
ol 
cooke
d 
whole 
HE, 
Peanu
t 
butter, 
Cow’s 
Milk 
(yoghu
rt), 
Fish 
(white
, 
cooke
d), 
Sesam
e 
(Tahini
), 
Wheat 
(whea
t 
based 
Exclusi
ve 
breastf
eeding 
and 
avoida
nce of 
all 6 
study 
foods 
until 6 
month
s of 
age 
3 12-
36 
I=31.9% 
C=92.9% 
HE 
allergy 
(OFC)  
RR 
0.69  
(95% 
CI 
0.40-
1.18) 
(p= 
0.17) 
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breakf
ast 
cereal) 
(4g of 
each 
allerge
n)  
Hens’ 
Egg 
Allerg
y 
Preve
ntion 
(HEAP
), 
Germa
ny 
RCT
, 
blin
ded 
(29
8)  
general 
populati
on 
23/406 
EW IgE 
≥0.35K
UA/L 
pasteu
rised 
raw 
HE 
white 
powde
r 
(7.5g) 
HE 
free 
diet 
placeb
o 
powde
r (rice) 
HE free 
diet 
4-12 12 I=86.7% 
C=93.5% 
HE 
sensiti
sation 
(sIgE)  
 
RR 
2.20  
(95% 
CI 
0.68-
7.14)  
(p=0.
24) 
Solids 
Timing 
for 
Allerg
y 
Resear
ch 
(STAR)
, 
Austra
lia 
RCT
, 
blin
ded 
(86) 
high risk  
(infants 
with 
moderat
e/ severe 
eczema) 
Not 
require
d per 
protoc
ol 
pasteu
rised 
raw 
whole 
HE 
powde
r 
(6.3g) 
placeb
o 
powde
r (rice) 
0-8 12 I=94% 
C=97%  
raw 
HE 
allergy 
(OFC) 
and 
Sensiti
sation 
(SPT) 
RR 
0.65 
(95% 
CI 
0.38-
1.11) 
(p=0 
.11) 
Startin
g Time 
for 
Egg 
Protei
n 
(STEP)
, 
Austra
lia 
RCT
, 
blin
ded 
(82
0) 
moderat
e risk 
(atopic 
mothers) 
Not 
require
d per 
protoc
ol 
pasteu
rised 
raw 
whole 
HE 
powde
r 
(2.8g) 
placeb
o 
powde
r (rice) 
4-10 12 I=84% 
C=85% 
raw 
HE 
allergy 
(OFC) 
and 
Sensiti
sation 
(sIgE) 
Adj 
RR 
0.75 
(95% 
CI 
0.48-
1.17 
(p=0.
20) 
Beatin
g Egg 
Allerg
y 
(BEAT)
, 
RCT
, 
blin
ded 
(25
moderat
e risk  
(1st 
degree 
relative 
with 
13/332 
SPT≥2
mm 
pasteu
rised 
raw 
whole 
HE 
powde
placeb
o 
powde
r (rice) 
HE free 
4-8 12 I=81% 
C=89% 
HE 
sensiti
sation 
(SPT)  
OR 
0.46 
(95% 
CI 
0.22-
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Austra
lia 
4) allergy) r 
(2.45g
)  
HE 
free 
diet 
diet 0.95)  
(p=0.
03) 
Two-
step 
egg 
introd
uction 
for 
preve
ntion 
of egg 
allergy 
in 
high-
risk 
infant
s with 
eczem
a 
(PETIT
), 
Japan 
RCT
, 
blin
ded 
(12
1) 
moderat
e risk  
(with 
atopic 
dermatiti
s) 
Not 
require
d per 
protoc
ol 
heate
d HE 
powde
r 
(0.175
g for 3 
month
s then 
0.875g 
for 3 
month
s) 
placeb
o 
powde
r 
(squas
h)  
4-12 12 I=92% 
C=93% 
HE 
allergy 
(OFC)  
RR 
0·222 
(95% 
CI 
0·08–
0·61) 
(p=0·
0012) 
 
 
Abbreviations: ARR, absolute risk reduction; Adj RR, Adjusted risk ratio; C, control; HE, hen’s egg; I, 
intervention; IgE, Immunoglobulin E; OFC, oral food challenge; OR, odds ratio; PN, peanut; RCT, 
randomised controlled trial; RR, relative risk; sIgE, specific immunoglobulin E; SPT, skin prick test. 
 
 
 
 
